For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Cortexin vs Dihexa

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CortexinDihexa
CategoryNootropic & CognitiveNootropic & Cognitive
Also known ascortexin polypeptide, cortexin-10, neuropeptide bioregulator, cortexin-5PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
EvidenceResearch-stagePreclinical only
Dosing range5mg–20mg mg, daily IM injection for 10-day courses10mg–20mg mg, Once daily (or every other day — long-lasting effects)
AdministrationIntramuscular injectionOral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common)
Key side effectsInjection site pain, Rare allergic reaction, Headache (transient), Mild dizzinessPotential for pro-proliferative effects — HGF/c-Met pathway promotes cell growth (theoretical cancer concern at high doses), Headache (uncommon), Mental fatigue if overdosed, Long half-life means effects accumulate — take every other day initially
Cited sources2 references2 references

Key differences

  • Evidence level differs: Cortexin is research-stage, while Dihexa is preclinical only.
  • Administration: Cortexin — Intramuscular injection; Dihexa — Oral (capsule), Transdermal (cream/lotion — lipophilicity makes this effective), Subcutaneous injection (less common).
  • Frequency: Cortexin is typically daily IM injection for 10-day courses; Dihexa is Once daily (or every other day — long-lasting effects).

How each works

Cortexin

Cortexin's multi-component neuropeptide mixture modulates neurotransmitter systems, improves cerebral blood flow, enhances neuroplasticity (BDNF upregulation), and exhibits antioxidant and anti-apoptotic activity in neuronal tissue. Russian stroke rehabilitation trials show improved neurological deficit scores and functional recovery with 10-day cortexin courses compared to standard care alone. The mechanism involves multiple parallel neuropeptide signaling pathways.

Dihexa

Dihexa (PNB-0408) was developed by Joseph Harding and colleagues at WSU as a metabolically stable angiotensin IV analog. It binds hepatocyte growth factor (HGF), potentiating its interaction with the c-Met receptor — a pathway critical for dendritic branching, synapse formation, and synaptic plasticity. In rodent Alzheimer's and scopolamine-impaired models, Dihexa restored cognitive performance at doses ~7 orders of magnitude lower than BDNF. It readily crosses the blood-brain barrier due to its lipophilicity, unlike BDNF itself.

Read the full Cortexin profileRead the full Dihexa profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.